Serveur d'exploration SRAS

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates.

Identifieur interne : 004044 ( Main/Merge ); précédent : 004043; suivant : 004045

Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates.

Auteurs : Shih-Jen Liu ; Chih-Hsiang Leng ; Shu-Pei Lien ; Hsiang-Yun Chi ; Chiung-Yi Huang ; Chang-Ling Lin ; Wei-Cheng Lian ; Chi-Ju Chen ; Shie-Liang Hsieh ; Pele Chong

Source :

RBID : pubmed:16494977

Descripteurs français

English descriptors

Abstract

The recombinant nucleocapsid (rN) protein of the coronavirus (CoV) responsible for severe acute respiratory syndrome (SARS) was cloned and expressed in Escherichia coli, extracted from cell lysates containing 6M urea, then purified by Ni(2+)-affinity chromatography. In animal immunogenicity studies, we found that most anti-rN protein antibodies were IgG2a in BALB/c mice vaccinated with rN emulsified in Montanide ISA-51 containing the synthetic oligodeoxynucleotide, CpG. In contrast, anti-rN protein antibodies of mice immunized with rN protein in PBS were found to mainly be IgG1. These results indicated that ISA-51/CpG-formulated rN protein was dramatically biased toward a Th1 immune response. To identify the B-cell immunodominant epitopes of the rN protein in the mouse and monkey, the reactivities of antisera raised against purified rN proteins formulated in ISA-51/CpG were tested with a panel of overlapping synthetic peptides covering the entire N protein sequence. Three immunodominant linear B-cell epitope regions were mapped to residues 166-180, 356-375, and 396-410 of the rN protein. When the reactivities of these peptides were screened with human sera from five SARS patients, peptides corresponding to residues 156-175 reacted strongly with sera from two of the SARS patients. These results indicated that the region around residues 156-175 of the N protein is immunogenic in the mouse, monkey, and human. We found that peptides corresponding to residues 1-30, 86-100, 306-320, and 351-365 contained murine immunodominant T-cell epitopes. To identify functional CTL epitopes of the N protein, BALB/c mice were immunized with peptides containing the H-2K(d) CTL motif emulsified in adjuvant ISA-51/CpG. Using an IFN-gamma secretion cell assay and analysis by flow cytometry, peptides containing residues 81-95 were found to be capable of stimulating both CD4(+) and CD8(+) cell proliferation in vitro. We also only observed that peptides corresponding to residues 336-350 were capable of stimulating IFN-gamma production in T-cell cultures derived from peripheral blood mononuclear cells (PBMCs) of macaques immunized with the rN protein emulsified in ISA/CpG adjuvant. Our current results together with those of others suggest that some immunodominant B-cell and T-cell epitopes are conserved in the mouse, monkey, and human. This information is very important for the development SARS diagnostic kits and a vaccine.

DOI: 10.1016/j.vaccine.2006.01.058
PubMed: 16494977

Links toward previous steps (curation, corpus...)


Links to Exploration step

pubmed:16494977

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates.</title>
<author>
<name sortKey="Liu, Shih Jen" sort="Liu, Shih Jen" uniqKey="Liu S" first="Shih-Jen" last="Liu">Shih-Jen Liu</name>
<affiliation>
<nlm:affiliation>Vaccine Research and Development Center, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli 350, Taiwan ROC.</nlm:affiliation>
<wicri:noCountry code="subField">Taiwan ROC</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Leng, Chih Hsiang" sort="Leng, Chih Hsiang" uniqKey="Leng C" first="Chih-Hsiang" last="Leng">Chih-Hsiang Leng</name>
</author>
<author>
<name sortKey="Lien, Shu Pei" sort="Lien, Shu Pei" uniqKey="Lien S" first="Shu-Pei" last="Lien">Shu-Pei Lien</name>
</author>
<author>
<name sortKey="Chi, Hsiang Yun" sort="Chi, Hsiang Yun" uniqKey="Chi H" first="Hsiang-Yun" last="Chi">Hsiang-Yun Chi</name>
</author>
<author>
<name sortKey="Huang, Chiung Yi" sort="Huang, Chiung Yi" uniqKey="Huang C" first="Chiung-Yi" last="Huang">Chiung-Yi Huang</name>
</author>
<author>
<name sortKey="Lin, Chang Ling" sort="Lin, Chang Ling" uniqKey="Lin C" first="Chang-Ling" last="Lin">Chang-Ling Lin</name>
</author>
<author>
<name sortKey="Lian, Wei Cheng" sort="Lian, Wei Cheng" uniqKey="Lian W" first="Wei-Cheng" last="Lian">Wei-Cheng Lian</name>
</author>
<author>
<name sortKey="Chen, Chi Ju" sort="Chen, Chi Ju" uniqKey="Chen C" first="Chi-Ju" last="Chen">Chi-Ju Chen</name>
</author>
<author>
<name sortKey="Hsieh, Shie Liang" sort="Hsieh, Shie Liang" uniqKey="Hsieh S" first="Shie-Liang" last="Hsieh">Shie-Liang Hsieh</name>
</author>
<author>
<name sortKey="Chong, Pele" sort="Chong, Pele" uniqKey="Chong P" first="Pele" last="Chong">Pele Chong</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2006">2006</date>
<idno type="RBID">pubmed:16494977</idno>
<idno type="pmid">16494977</idno>
<idno type="doi">10.1016/j.vaccine.2006.01.058</idno>
<idno type="wicri:Area/PubMed/Corpus">002335</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002335</idno>
<idno type="wicri:Area/PubMed/Curation">002335</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002335</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002148</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002148</idno>
<idno type="wicri:Area/Ncbi/Merge">001391</idno>
<idno type="wicri:Area/Ncbi/Curation">001391</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001391</idno>
<idno type="wicri:doubleKey">0264-410X:2006:Liu S:immunological:characterizations:of</idno>
<idno type="wicri:Area/Main/Merge">004044</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates.</title>
<author>
<name sortKey="Liu, Shih Jen" sort="Liu, Shih Jen" uniqKey="Liu S" first="Shih-Jen" last="Liu">Shih-Jen Liu</name>
<affiliation>
<nlm:affiliation>Vaccine Research and Development Center, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli 350, Taiwan ROC.</nlm:affiliation>
<wicri:noCountry code="subField">Taiwan ROC</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Leng, Chih Hsiang" sort="Leng, Chih Hsiang" uniqKey="Leng C" first="Chih-Hsiang" last="Leng">Chih-Hsiang Leng</name>
</author>
<author>
<name sortKey="Lien, Shu Pei" sort="Lien, Shu Pei" uniqKey="Lien S" first="Shu-Pei" last="Lien">Shu-Pei Lien</name>
</author>
<author>
<name sortKey="Chi, Hsiang Yun" sort="Chi, Hsiang Yun" uniqKey="Chi H" first="Hsiang-Yun" last="Chi">Hsiang-Yun Chi</name>
</author>
<author>
<name sortKey="Huang, Chiung Yi" sort="Huang, Chiung Yi" uniqKey="Huang C" first="Chiung-Yi" last="Huang">Chiung-Yi Huang</name>
</author>
<author>
<name sortKey="Lin, Chang Ling" sort="Lin, Chang Ling" uniqKey="Lin C" first="Chang-Ling" last="Lin">Chang-Ling Lin</name>
</author>
<author>
<name sortKey="Lian, Wei Cheng" sort="Lian, Wei Cheng" uniqKey="Lian W" first="Wei-Cheng" last="Lian">Wei-Cheng Lian</name>
</author>
<author>
<name sortKey="Chen, Chi Ju" sort="Chen, Chi Ju" uniqKey="Chen C" first="Chi-Ju" last="Chen">Chi-Ju Chen</name>
</author>
<author>
<name sortKey="Hsieh, Shie Liang" sort="Hsieh, Shie Liang" uniqKey="Hsieh S" first="Shie-Liang" last="Hsieh">Shie-Liang Hsieh</name>
</author>
<author>
<name sortKey="Chong, Pele" sort="Chong, Pele" uniqKey="Chong P" first="Pele" last="Chong">Pele Chong</name>
</author>
</analytic>
<series>
<title level="j">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
<imprint>
<date when="2006" type="published">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Adjuvants, Immunologic</term>
<term>Animals</term>
<term>Antibodies, Viral (blood)</term>
<term>CD4-Positive T-Lymphocytes (immunology)</term>
<term>CD8-Positive T-Lymphocytes (immunology)</term>
<term>Enzyme-Linked Immunosorbent Assay</term>
<term>Epitope Mapping</term>
<term>Epitopes, B-Lymphocyte</term>
<term>Epitopes, T-Lymphocyte</term>
<term>Escherichia coli (genetics)</term>
<term>Female</term>
<term>Humans</term>
<term>Immunodominant Epitopes</term>
<term>Immunoglobulin G (blood)</term>
<term>Lymphocyte Subsets (immunology)</term>
<term>Macaca</term>
<term>Mannitol (analogs & derivatives)</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Nucleocapsid Proteins (administration & dosage)</term>
<term>Nucleocapsid Proteins (immunology)</term>
<term>Nucleocapsid Proteins (isolation & purification)</term>
<term>Oleic Acids</term>
<term>Oligodeoxyribonucleotides</term>
<term>SARS Virus (genetics)</term>
<term>SARS Virus (immunology)</term>
<term>Severe Acute Respiratory Syndrome (immunology)</term>
<term>Severe Acute Respiratory Syndrome (prevention & control)</term>
<term>Vaccines, Subunit (administration & dosage)</term>
<term>Vaccines, Subunit (immunology)</term>
<term>Vaccines, Synthetic (administration & dosage)</term>
<term>Vaccines, Synthetic (immunology)</term>
<term>Viral Vaccines (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Acides oléiques</term>
<term>Adjuvants immunologiques</term>
<term>Animaux</term>
<term>Anticorps antiviraux (sang)</term>
<term>Cartographie épitopique</term>
<term>Déterminants antigéniques des lymphocytes B</term>
<term>Déterminants antigéniques des lymphocytes T</term>
<term>Escherichia coli (génétique)</term>
<term>Femelle</term>
<term>Humains</term>
<term>Immunoglobuline G (sang)</term>
<term>Lymphocytes T CD4+ (immunologie)</term>
<term>Lymphocytes T CD8+ (immunologie)</term>
<term>Macaca</term>
<term>Mannitol (analogues et dérivés)</term>
<term>Oligodésoxyribonucléotides</term>
<term>Protéines nucléocapside (administration et posologie)</term>
<term>Protéines nucléocapside (immunologie)</term>
<term>Protéines nucléocapside (isolement et purification)</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Sous-populations de lymphocytes (immunologie)</term>
<term>Syndrome respiratoire aigu sévère ()</term>
<term>Syndrome respiratoire aigu sévère (immunologie)</term>
<term>Test ELISA</term>
<term>Vaccins antiviraux (immunologie)</term>
<term>Vaccins sous-unitaires (administration et posologie)</term>
<term>Vaccins sous-unitaires (immunologie)</term>
<term>Vaccins synthétiques (administration et posologie)</term>
<term>Vaccins synthétiques (immunologie)</term>
<term>Virus du SRAS (génétique)</term>
<term>Virus du SRAS (immunologie)</term>
<term>Épitopes immunodominants</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en">
<term>Nucleocapsid Proteins</term>
<term>Vaccines, Subunit</term>
<term>Vaccines, Synthetic</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en">
<term>Mannitol</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en">
<term>Antibodies, Viral</term>
<term>Immunoglobulin G</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en">
<term>Nucleocapsid Proteins</term>
<term>Vaccines, Subunit</term>
<term>Vaccines, Synthetic</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="isolation & purification" xml:lang="en">
<term>Nucleocapsid Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en">
<term>Adjuvants, Immunologic</term>
<term>Epitopes, B-Lymphocyte</term>
<term>Epitopes, T-Lymphocyte</term>
<term>Immunodominant Epitopes</term>
<term>Oleic Acids</term>
<term>Oligodeoxyribonucleotides</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr">
<term>Protéines nucléocapside</term>
<term>Vaccins sous-unitaires</term>
<term>Vaccins synthétiques</term>
</keywords>
<keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr">
<term>Mannitol</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en">
<term>Escherichia coli</term>
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr">
<term>Escherichia coli</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr">
<term>Lymphocytes T CD4+</term>
<term>Lymphocytes T CD8+</term>
<term>Protéines nucléocapside</term>
<term>Sous-populations de lymphocytes</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Vaccins antiviraux</term>
<term>Vaccins sous-unitaires</term>
<term>Vaccins synthétiques</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en">
<term>CD4-Positive T-Lymphocytes</term>
<term>CD8-Positive T-Lymphocytes</term>
<term>Lymphocyte Subsets</term>
<term>SARS Virus</term>
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr">
<term>Protéines nucléocapside</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en">
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr">
<term>Anticorps antiviraux</term>
<term>Immunoglobuline G</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Animals</term>
<term>Enzyme-Linked Immunosorbent Assay</term>
<term>Epitope Mapping</term>
<term>Female</term>
<term>Humans</term>
<term>Macaca</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Acides oléiques</term>
<term>Adjuvants immunologiques</term>
<term>Animaux</term>
<term>Cartographie épitopique</term>
<term>Déterminants antigéniques des lymphocytes B</term>
<term>Déterminants antigéniques des lymphocytes T</term>
<term>Femelle</term>
<term>Humains</term>
<term>Macaca</term>
<term>Oligodésoxyribonucléotides</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Test ELISA</term>
<term>Épitopes immunodominants</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">The recombinant nucleocapsid (rN) protein of the coronavirus (CoV) responsible for severe acute respiratory syndrome (SARS) was cloned and expressed in Escherichia coli, extracted from cell lysates containing 6M urea, then purified by Ni(2+)-affinity chromatography. In animal immunogenicity studies, we found that most anti-rN protein antibodies were IgG2a in BALB/c mice vaccinated with rN emulsified in Montanide ISA-51 containing the synthetic oligodeoxynucleotide, CpG. In contrast, anti-rN protein antibodies of mice immunized with rN protein in PBS were found to mainly be IgG1. These results indicated that ISA-51/CpG-formulated rN protein was dramatically biased toward a Th1 immune response. To identify the B-cell immunodominant epitopes of the rN protein in the mouse and monkey, the reactivities of antisera raised against purified rN proteins formulated in ISA-51/CpG were tested with a panel of overlapping synthetic peptides covering the entire N protein sequence. Three immunodominant linear B-cell epitope regions were mapped to residues 166-180, 356-375, and 396-410 of the rN protein. When the reactivities of these peptides were screened with human sera from five SARS patients, peptides corresponding to residues 156-175 reacted strongly with sera from two of the SARS patients. These results indicated that the region around residues 156-175 of the N protein is immunogenic in the mouse, monkey, and human. We found that peptides corresponding to residues 1-30, 86-100, 306-320, and 351-365 contained murine immunodominant T-cell epitopes. To identify functional CTL epitopes of the N protein, BALB/c mice were immunized with peptides containing the H-2K(d) CTL motif emulsified in adjuvant ISA-51/CpG. Using an IFN-gamma secretion cell assay and analysis by flow cytometry, peptides containing residues 81-95 were found to be capable of stimulating both CD4(+) and CD8(+) cell proliferation in vitro. We also only observed that peptides corresponding to residues 336-350 were capable of stimulating IFN-gamma production in T-cell cultures derived from peripheral blood mononuclear cells (PBMCs) of macaques immunized with the rN protein emulsified in ISA/CpG adjuvant. Our current results together with those of others suggest that some immunodominant B-cell and T-cell epitopes are conserved in the mouse, monkey, and human. This information is very important for the development SARS diagnostic kits and a vaccine.</div>
</front>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004044 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 004044 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    Main
   |étape=   Merge
   |type=    RBID
   |clé=     pubmed:16494977
   |texte=   Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i   -Sk "pubmed:16494977" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1 

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021